• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • Clinical Trial Listings
    • What are Clinical Trials?
    • Become a Clinical Trial Volunteer
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Market Research
    • Benchmark Reports
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • White Papers
    • SOPs
  • White Papers
  • Clinical Trial Listings
  • Advertise
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Sanofi appoints Olivier Brandicourt CEO

Sanofi appoints Olivier Brandicourt CEO

February 23, 2015
CenterWatch Staff

Sanofi’s board of directors unanimously has appointed Olivier Brandicourt CEO.

Olivier Brandicourt has 28 years of global experience in the pharmaceutical industry, most recently as chairman of the board of management of Bayer HealthCare and member of the executive council of Bayer. Previously, Brandicourt held numerous positions of increasing responsibility within major global pharmaceutical groups such as Parke-Davis/Warner-Lambert and Pfizer. Brandicourt was a member of Pfizer's global executive leadership team from 2010-2013. 

A physician by training, Olivier Brandicourt's career includes several senior positions in Europe, Canada and the U.S. As the head of various healthcare divisions, he has a broad range of experience and knowledge of the pharmaceutical industry and has led the launch of numerous new medicines and the completion of strategic acquisitions and integrations.

Serge Weinberg, chairman of the board of directors, Sanofi, said, "Sanofi undertook a rigorous selection process to identify the right person to lead Sanofi forward at an important time for our company. I am very pleased that Olivier Brandicourt will be the next CEO of Sanofi. Olivier Brandicourt's strong experience combined with his international profile, deep knowledge of U.S. and emerging healthcare markets and his capability to unite teams will provide new dynamism to Sanofi's strategy of diversification and innovation."

In agreement with his former employer, Brandicourt will start April 2, 2015.

    Upcoming Events

    • 05Dec

      Thriving in Clinical Research – Overcoming Common Challenges as a Site: Part 3 – Site Resourcing

    • 14Apr

      MAGI 2024: The Clinical Research Conference

    Featured Products

    • Surviving an FDA GCP Inspection

      Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

    • Best Practices for Clinical Trial Site Management

      Best Practices for Clinical Trial Site Management

    Featured Stories

    • Jonathan Seltzer

      Thought Leadership: Remote Patient Monitoring Gives New View of Safety in Cardiac Clinical Trials

    • Quality_Compass-360x240.png

      Ask the Experts: Applying Quality by Design to Protocols

    • Obesity Treatment Patient

      Clinical Trials Need Greater Representation of Obese Patients, Experts Say

    • Modernize-360x240.png

      FDA IT Modernization Plan Prioritizes Data-Sharing, AI, Collaboration and More

    Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

    The information you need to adapt your monitoring plan to changing times.

    Learn More Here
    • About Us
    • Contact Us
    • Privacy Policy
    • Do Not Sell or Share My Data

    Footer Logo

    300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

    Phone 703.538.7600 – Toll free 888.838.5578

    Copyright © 2023. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing